Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:28248300  

PNPLA1 has a crucial role in skin barrier function by directing acylceramide biosynthesis.

Tetsuya Hirabayashi | Tatsuki Anjo | Arisa Kaneko | Yuuya Senoo | Akitaka Shibata | Hiroyuki Takama | Kohei Yokoyama | Yasumasa Nishito | Tomio Ono | Choji Taya | Kazuaki Muramatsu | Kiyoko Fukami | Agustí Muñoz-Garcia | Alan R Brash | Kazutaka Ikeda | Makoto Arita | Masashi Akiyama | Makoto Murakami
Nature communications | 2017

Mutations in patatin-like phospholipase domain-containing 1 (PNPLA1) cause autosomal recessive congenital ichthyosis, but the mechanism involved remains unclear. Here we show that PNPLA1, an enzyme expressed in differentiated keratinocytes, plays a crucial role in the biosynthesis of ω-O-acylceramide, a lipid component essential for skin barrier. Global or keratinocyte-specific Pnpla1-deficient neonates die due to epidermal permeability barrier defects with severe transepidermal water loss, decreased intercellular lipid lamellae in the stratum corneum, and aberrant keratinocyte differentiation. In Pnpla1-/- epidermis, unique linoleate-containing lipids including acylceramides, acylglucosylceramides and (O-acyl)-ω-hydroxy fatty acids are almost absent with reciprocal increases in their putative precursors, indicating that PNPLA1 catalyses the ω-O-esterification with linoleic acid to form acylceramides. Moreover, acylceramide supplementation partially rescues the altered differentiation of Pnpla1-/- keratinocytes. Our findings provide valuable insight into the skin barrier formation and ichthyosis development, and may contribute to novel therapeutic strategies for treatment of epidermal barrier defects.

Pubmed ID: 28248300

Research resources used in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR051968

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


QIAGEN (tool)

RRID:SCR_008539

A commercial organization which provides assay technologies to isolate DNA, RNA, and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.

View all literature mentions

Matreya LLC (tool)

RRID:SCR_013390

An Antibody supplier

View all literature mentions

Agilent Technologies (tool)

RRID:SCR_013575

Company provides laboratories worldwide with analytical instruments and supplies, clinical and diagnostic testing services, consumables, applications and expertise in life sciences and applied chemical markets.

View all literature mentions

Wako (tool)

RRID:SCR_013651

An Antibody supplier

View all literature mentions

C57BL/6N (tool)

RRID:MGI:2159965

laboratory mouse with name C57BL/6N from MGI.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

Pnpla1tm1a(KOMP)Wtsi (organism)

RRID:IMSR_KOMP:CSD79620

gene symbol note: patatin-like phospholipase domain containing 1 mutant strain targeted mutation 1a, Wellcome Trust Sanger Institute This is a legacy resource.

View all literature mentions